Welcome to our dedicated page for Indaptus Therapeutics news (Ticker: INDP), a resource for investors and traders seeking the latest updates and insights on Indaptus Therapeutics stock.
Indaptus Therapeutics develops clinical-stage immunotherapies for cancer and viral infections using its Decoy bacterial platform. The company’s lead candidate, Decoy20, is based on attenuated and killed, non-pathogenic Gram-negative bacteria designed to activate innate and adaptive immune responses, with a focus on solid tumors.
Recurring news for Indaptus covers clinical updates from the INDP-D101 program, including Decoy20 evaluation as monotherapy and in combination with the PD-1 inhibitor tislelizumab. Company updates also include preclinical research on immune-cell activation, quarterly financial results, private placements, convertible notes and warrants, at-the-market financing, reverse stock split actions, Nasdaq compliance matters, and scientific or investor conference presentations.
Indaptus Therapeutics (Nasdaq: INDP) announced CEO Jeffrey Meckler will present at the H.C. Wainwright BioConnect 2022 Virtual Conference on January 10 at 7:00 a.m. ET. The presentation will be pre-recorded and available via an audio webcast on the company's website, archived for approximately 90 days. Indaptus focuses on immunotherapy, using patented technology to activate immune responses for anti-tumor and anti-viral treatments. Their lead candidate, Decoy20, has undergone successful GMP manufacturing and is progressing with IND enabling studies.
Indaptus Therapeutics (Nasdaq: INDP) announces Dr. Boyan Litchev as the new Chief Medical Officer, effective January 31, 2022. Dr. Litchev brings over 20 years of experience in clinical oncology and medical leadership, having previously served at Shoreline Biosciences and Poseida Therapeutics. He will lead clinical strategies and the upcoming Phase 1 study of Decoy20, anticipated in 2022. The appointment is seen as a pivotal move towards advancing Indaptus's innovative immunotherapy platform aimed at treating various diseases through enhanced immune activation.
Indaptus Therapeutics, Inc. (Nasdaq: INDP) announces the appointment of Mark Gilbert, M.D., formerly Chief Medical Officer at Juno Therapeutics, to its Board of Directors, effective immediately. He replaces Hoonmo Lee, who has stepped down. Dr. Gilbert brings significant oncology expertise, having led pioneering CAR-T cell therapy developments. CEO Jeffrey Meckler expressed confidence that Dr. Gilbert’s experience will enhance the company’s immunotherapy pipeline. Indaptus utilizes patented technology aimed at activating both innate and adaptive immunity for cancer treatment.
Indaptus Therapeutics (Nasdaq: INDP) reported financial results for Q3 2021, highlighting a transformative quarter with the merger with Decoy Biosystems and a $30 million private placement. Research and development expenses decreased by 48% year-over-year to approximately $0.7 million, while general and administrative expenses surged by 1,260% to about $2.7 million. The company reported a loss per share of $0.81, slightly higher than $0.79 for Q3 2020. As of September 30, 2021, cash and cash equivalents stood at approximately $41.9 million, up from $1.6 million at the end of 2020.
Indaptus Therapeutics announced a significant advancement as the United States Patent and Trademark Office has allowed claims for their platform technology aimed at treating HBV and HIV infections. The patent, titled 'Methods of Treatment of Infections Using Bacteria,' grants broad protection for their innovative approach. This development validates Indaptus' strategy to activate immune responses against viral infections. The company aims to further explore partnerships for technology development, following promising pre-clinical results demonstrating enhanced therapeutic efficacy.